Osimertinib

Common brands: Tagrisso, Iressa, Carboplatin, Kyxata, Pemetrexed

Top reporter: Astrazeneca Pharmaceuticals Lp

Kinase Inhibitor [EPC]Platinum-based Drug [EPC]Corticosteroid [EPC]Folate Analog Metabolic Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitor [EPC]
30,472
Total Reports
24,279
Serious Reports
13,492
Death Reports
30
Reported Reactions
Death Report Ratio: High (44.28%)

Patient Demographics

Male
8,974
Female
17,330

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Osimertinib.

# Reaction Reports % of Total
1 DEATH 11,120
36.2%
2 MALIGNANT NEOPLASM PROGRESSION 3,142
10.2%
3 DIARRHOEA 1,593
5.2%
4 DRUG RESISTANCE 1,082
3.5%
5 FATIGUE 968
3.1%
6 RASH 884
2.9%
7 OFF LABEL USE 757
2.5%
8 DECREASED APPETITE 756
2.5%
9 DRUG INEFFECTIVE 717
2.3%
10 DYSPNOEA 712
2.3%
11 DISEASE PROGRESSION 711
2.3%
12 NAUSEA 680
2.2%
13 METASTASES TO CENTRAL NERVOUS SYSTEM 642
2.1%
14 ASTHENIA 585
1.9%
15 INTERSTITIAL LUNG DISEASE 579
1.9%
16 PLEURAL EFFUSION 518
1.7%
17 ACQUIRED GENE MUTATION 473
1.5%
18 WEIGHT DECREASED 469
1.5%
19 PNEUMONIA 442
1.4%
20 VOMITING 428
1.4%
21 COUGH 398
1.3%
22 PAIN 382
1.2%
23 PNEUMONITIS 377
1.2%
24 DRY SKIN 371
1.2%
25 PYREXIA 352
1.1%
26 FALL 338
1.1%
27 THROMBOSIS 334
1.1%
28 MYELOSUPPRESSION 322
1.0%
29 PLATELET COUNT DECREASED 307
1.0%
30 DIZZINESS 304
1.0%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.